海南葫芦娃药业集团股份有限公司 证券代码：605199 证券简称：葫芦娃 公告编号：2024-057 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）担保的基本情况 为满足广西维威生产经营的需要，广西维威拟向招商银行股份有限公司南宁分行申 请贷款，贷款期限在一年范围内，具体以银行借款合同为准，公司为其提供连带责任保 证担保，担保的债权最高额限度为人民币5,000 万元以及相关的利息、罚息、复息、违 约金、迟延履行金、保理费用、实现担保权和债权的费用和其他相关费用提供担保。 （二）上述担保的内部决策程序 2024年5月22日，公司召开了2023年度股东大会，审议通过了《关于公司及子公司向 银行申请2024年度综合授信额度及提供相应担保额度预计的议案》。同意公司及控股子 公司拟向银行等金融机构或其他机构新增申请总计不超过15亿元的贷款融资额度，在上 述总额度内，公司、子公司分别对资产负债率70%以上（含70%）的子公司的授信、借款 1 被担保人名称及是否为上市 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-058 海南葫芦娃药业集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 海南葫芦娃药业集团股份有限公司（以下简称"公司"）控股股东海南葫芦娃 投资发展有限公司（以下简称"葫芦娃投资"）持有公司 167,079,000 股，占公司总 股本的 41.76%；本次解质押股份 27,875,456 股，占其持股总数的 16.68%,占公司总股 本 6.97%。 本次解除质押后，葫芦娃投资及其一致行动人累计质押股份数量 61,456,000 股，占葫芦娃投资及其一致行动人合计持股数量的 20.03%，占公司总股本 15.36%。 一、本次股份解除质押的情况 公司近日收到控股股东葫芦娃投资的通知，获悉其所持有本公司的股份进行解质 押，具体事项如下。 | 股东名称 | 葫芦娃投资 | | --- | --- | | 本次解质押股份 | 27,875,456 | | 占其持股份比例 | 16.68% | | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：605199 证券简称：葫芦娃 公告编号：2024-056 海南葫芦娃药业集团股份有限公司 关于为全资子公司提供担保的公告 一、担保情况概述 （一）担保的基本情况 为满足广西维威生产经营的需要，广西维威拟向兴业银行股份有限公司南宁分行申 请4,000万元的贷款，贷款期限在一年范围内，具体以银行借款合同为准，公司对该最高 主债权额项下的所有债权余额（含本金、利息、罚息、复利、违约金、损害赔偿金、债 权人实现债权的费用等）承担连带保证责任。 （二）上述担保的内部决策程序 2024年5月22日，公司召开了2023年度股东大会，审议通过了《关于公司及子公司向 银行申请2024年度综合授信额度及提供相应担保额度预计的议案》。同意公司及控股子 公司拟向银行等金融机构或其他机构新增申请总计不超过15亿元的贷款融资额度，在上 述总额度内，公司、子公司分别对资产负债率70%以上（含70%）的子公司的授信、借款 1 被担保人名称及是否为上市公司关联人：广西维威制药有限公司（ ...

上海证券交易所(以下简称"上交所") 上市审核委员会于 2024 年 8 月 26 日召开 2024 年第 21 次审议会议,对海南葫芦娃药业集团股 份有限公司（以下简称"公司"）向不特定对象发行可转换公司债券 的申请进行了审议。根据会议审议结果，公司本次向不特定对象发行 可转换公司债券的申请不符合发行条件、上市条件或信息披露要求。 具体内容详见公司 2024 年 8 月 27 日在上交所网站(www.sse.com.cn) 披露的《关于向不特定对象发行可转换公司债券上海证券交易所上市 审核委员会审议会议结果的公告》 (公告编号: 2024-048)。 证券代码：605199 证券简称：葫芦娃 公告编号：2024-055 海南葫芦娃药业集团股份有限公司 关于收到上海证券交易所《关于终止对海南葫芦娃药业集 团股份有限公司向不特定对象发行可转换公司债券审核的 决定》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 海南葫芦娃药业集团股份有限公司董事会 2024 年 9 月 8 日 公司于 2024 年 9 月 6 ...

Sales Performance - The sales of pediatric lung heat cough granules increased by 50% in the first half of the year, driven by strong demand in the medical sector, especially during the winter and around the Spring Festival [3] - The sales of Ke Ke Pian, another core product, approached 50 million yuan, showing a slight decline compared to the same period last year due to tight supply of raw materials [3][5] - The company expects sales of core products to increase in the autumn and winter seasons, particularly after September, due to a rise in respiratory diseases [3][4] Product Development - In the first half of 2024, the company received production registration approvals for 7 products and passed consistency evaluations for 2 products, with 34 new products under application [4] - The company is focusing on four strategies for research and development: targeting children's health, deepening traditional Chinese medicine, expanding indications, and aligning with national policy directions [4] Future Growth Potential - The company is cultivating potential products to enrich its product line, with the compound lysine granules being a key focus for the children's health market [4] - The introduction of new packaging for the intestinal inflammation granules aims to cater to both children and adults, expanding market reach [4] - The company is leveraging the advantages of the Hainan Free Trade Port to promote export business, contributing to future growth [4][5] Raw Material Supply - In May 2023, the company acquired a 51% stake in Jiangxi Rongxing Pharmaceutical to stabilize the supply and price fluctuations of raw materials [5] - The company plans to produce more raw materials for its formulations at Jiangxi Rongxing, enhancing its upstream supply chain [5]

海南葫芦娃药业集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 29 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地 了解公司 2024 年半年度的经营成果、财务状况，公司计划于 2024 年 09 月 12 日下午 13:00-14:30 举行 2024 年半年度业绩说明会，就投资者关心 的问题进行交流。 一、 说明会类型 本次投资者说明会以视频录播结合网络文字互动的方式召开，公司将 证券代码：605199 证券简称：葫芦娃 公告编号：2024-054 海南葫芦娃药业集团股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 09 月 05 日(星期四) 至 09 月 11 日(星期三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hu luwa@huluwayaoye.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 会议召开时间：2024 年 09 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥846,714,106.03, a decrease of 7.36% compared to ¥913,979,323.00 in the same period last year[15]. - The net profit attributable to shareholders of the listed company was ¥78,751,617.40, representing an increase of 28.33% from ¥61,364,614.89 in the previous year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥42,190,044.38, down 11.91% from ¥47,893,434.59 in the same period last year[15]. - The net cash flow from operating activities was -¥151,118,833.90, compared to -¥160,301,194.74 in the previous year, indicating an improvement[15]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,149,277,874.77, an increase of 2.58% from ¥1,120,385,678.79 at the end of the previous year[15]. - Total assets at the end of the reporting period were ¥3,108,986,927.32, reflecting a 1.58% increase from ¥3,060,548,675.78 at the end of the previous year[15]. - Basic and diluted earnings per share increased by 33.33% year-on-year to CNY 0.20, driven by the transfer of subsidiary equity and government subsidies[16]. - The weighted average return on equity rose by 0.97 percentage points to 6.84%[16]. - Non-recurring gains and losses totaled CNY 36,561,573.02 after tax, with significant contributions from government subsidies and asset disposals[18]. Research and Development - The company is focusing on R&D investments in children's medicine, with ongoing projects targeting infectious diseases and digestive issues[21]. - R&D investment reached 77.24 million yuan, a significant increase of 96.00% year-on-year, with ongoing progress in technological innovation[49]. - The company is actively developing new pediatric formulations, including inhalation preparations and controlled-release formulations, targeting high-end markets[45]. - The company has a strong focus on research and development, with national-level postdoctoral research stations and engineering technology research centers established[40]. - The company is advancing clinical trials for several new pediatric drugs, including the pediatric cough syrup, which has completed Phase II trials and is moving to Phase III[50]. Market and Product Development - The company currently has 53 children's drug products in production, covering a wide age range from 0 to 14 years[20]. - Seven health food products have been successfully approved for market, including various vitamin and mineral supplements[22]. - The company has established a comprehensive product matrix under four major brands to meet diverse market needs[19]. - The star product, Pediatric Lung Heat Cough and Wheezing Granules, has gained significant trust among parents and healthcare professionals[20]. - The company has launched 7 new products during the reporting period, including Ibuprofen Suspension and Cefdinir Granules, enhancing its product portfolio and supporting sustainable development[42]. Operational Efficiency - The company has implemented a production model combining "sales-driven production" and "reasonable inventory," ensuring quality management in accordance with the latest GMP standards[28]. - The newly established Meian Children's Medicine smart manufacturing plant received GMP certification during the reporting period, enhancing production efficiency and product quality through automation and intelligent management systems[28]. - The company has expanded its sales channels, including direct sales to large pharmaceutical chains and e-commerce platforms, to increase market coverage[30]. - The traditional distribution model has been gradually shifted to a distribution merchant model to comply with national policies, enhancing efficiency in delivering products to medical institutions[32]. - The company emphasizes quality in procurement, implementing strict supplier evaluations and dynamic management to ensure compliance with quality standards[27]. Environmental Responsibility - The company reported no exceedance of emission standards for volatile organic compounds, particulate matter, and other pollutants in the surrounding air[77]. - The total amount of hazardous waste generated in the first half of 2024 was 5.5771 tons for medical waste and 24.596 tons for pharmaceutical waste[79]. - The company has implemented measures to ensure that all emissions and discharges comply with national and local environmental standards[81]. - The company has established solid waste storage facilities for both general industrial solid waste and hazardous waste, all operating normally[90]. - The company is committed to reducing carbon emissions through low-nitrogen boiler modifications and energy management for electrical equipment[98]. Corporate Governance - The company has established a framework for accountability if commitments are not met, including public apologies and potential penalties[115]. - The company will ensure compliance with all legal and regulatory requirements regarding shareholding and reduction commitments[106]. - The controlling shareholder ensures that there are no direct or indirect competitive activities with subsidiaries of the company[109]. - The company has measures in place to compensate for any dilution of immediate returns, with commitments from directors and senior management linked to the execution of these measures[114]. - The company has not experienced any major changes in its integrity status during the reporting period[120]. Financial Position - Total current assets decreased to ¥1,317,783,272.17 from ¥1,442,585,174.05, a decline of approximately 8.7%[135]. - Cash and cash equivalents decreased to ¥312,916,084.83 from ¥522,689,865.24, a decrease of about 40.0%[135]. - Total liabilities increased to ¥1,919,930,370.10 from ¥1,901,175,403.43, an increase of about 1.0%[137]. - The total owner's equity at the end of the reporting period was 1,112,033,909.02, showing an increase from 1,015,265,708.78 at the end of the previous year[160]. - The company reported a total of 294,645,573.54 RMB in cash and cash equivalents at the end of the period, compared to 217,096,923.33 RMB in the previous year[148].

证券代码：605199 证券简称：葫芦娃 公告编号：2024-051 海南葫芦娃药业集团股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第三届董事会第四 次会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关规定，会议合 法有效。 （二）会议通知和材料于 2024 年 8 月 16 日以邮件方式发出。 （三）会议于 2024 年 8 月 28 日在海南省海口市秀英区安读一路 30 号公司会议室 以现场结合通讯方式召开。 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人（其中以通讯表决方式 出席会议的董事 2 人）。 （五）本次董事会会议由董事长刘景萍女士主持，公司全体监事、高级管理人员列 席会议。 二、董事会会议审议情况 （一）审议通过了《关于公司 2024 年半年度报告及其摘要的议案》 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海南葫 芦娃药 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-049 海南葫芦娃药业集团股份有限公司 规格：3ml: 0.3g 上市许可持有人：海南葫芦娃药业集团股份有限公司 关于获得吸入用乙酰半胱氨酸溶液药品注册证书的公告 受理号：CYHS2300807 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 药品批准文号：国药准字 H20244705 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的关于吸入用乙酰半胱氨酸溶液的《药品注册 证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：吸入用乙酰半胱氨酸溶液 剂型：吸入制剂 注册分类：化学药品 4 类 公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安全。上 述药品获得《药品注册证书》，将进一步丰富公司产品线，对公司的发展起到积极作用。 由于医药行业的特点，药品的前期研发以及产品从研制到投产的周期长、环节多，而且 药品获得证书后生产和销售也容易受到国家政策、市场环境变化等影响，药品的销售业 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605199 证券简称：葫芦娃 公告编号：2024-050 海南葫芦娃药业集团股份有限公司 关于全资子公司获得拉考沙胺口服溶液药品注册证书的公告 审批结论： 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所 附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、药品研发及相关 海南葫芦娃药业集团股份有限公司全资子公司广西维威制药有限公司（以下简称"广西 维威"）近日收到国家药品监督管理局（以下简称"国家药监局"）核准签发的关于拉考沙 胺口服溶液的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：拉考沙胺口服溶液 剂型：口服溶液剂 注册分类：化学药品 4 类 规格：200ml：2g 上市许可持有人：广西维威制药有限公司 受理号：CYHS2301238 药品批准文号：国药准字 H20244711 拉考沙胺口服溶液由 UCB Pharma S ...